TD Cowen Sticks to Their Buy Rating for Rapport Therapeutics, Inc. (RAPP)
Rapport Therapeutics GAAP EPS of -$1.70 Misses by $1.02
Express News | Rapport Therapeutics Ended The Quarter With $336.1M In Cash, Cash Equivalents, And Short-term Investments, Excluding Restricted Cash, Which Is Expected To Fund Operations Through The End Of 2026
Express News | Rapport Therapeutics Q2 2024 GAAP EPS $(1.70) Misses $(0.68) Estimate
Rapport Therapeutics | 10-Q: Quarterly report
Rapport Therapeutics: Runway To Fund Operations Through End of 2026 >RAPP
Rapport Therapeutics 2Q Loss $18.1M >RAPP
Express News | Rapport Therapeutics Reports Second Quarter Financials and Provides Business Update
Press Release: Rapport Therapeutics Reports Second Quarter Financials and Provides Business Update
Rapport Therapeutics to Present Data for TARPγ8 AMPAR Negative Modulator at IASP 2024 World Congress on Pain
Rapport Therapeutics(RAPP.US) Director Buys US$1.08 Million in Common Stock
Stifel Starts Rapport at Buy, Cites Lead Drug Candidate RAP-219
TD Cowen Initiates Rapport Therapeutics(RAPP.US) With Buy Rating
Rapport Therapeutics Analyst Ratings
Express News | Rapport Therapeutics Inc : TD Cowen Initiates Coverage With Buy Rating
Stifel Initiates Rapport Therapeutics(RAPP.US) With Buy Rating, Announces Target Price $35
Jefferies Initiates Rapport Therapeutics(RAPP.US) With Buy Rating, Announces Target Price $35
Buy Rating for Rapport Therapeutics: Disruptive CNS Treatments and Promising Drug Efficacy
Express News | Rapport Therapeutics Inc : Jefferies Initiates Coverage With Buy Rating; Target Price $35
Express News | James I. Healy Reports 5.5% Stake in Rapport Therapeutics Inc as of June 10, 2024- SEC Filing
No Data